ReviewInternational journal of molecular sciences2019

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.

Vjera Ninčević et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.